Announcing a New Educational Program by the American Headache Society

The Resident Education Program launches this month There are about 500 certified headache specialists in the United States, and as many as 38 million people living with headache disorders and other neurological diseases. Given the prevalence of headache disorders and the impact they have on our healthcare system and economy, we believe a strong foundation in neurology residency training is necessary in order to appropriately diagnose and treat patients presenting with all types of headache disorders. That is why the American Headache Society is launching a long-term Resident Education Program to better educate neurology residents about migraine and related headache...

Complementary and Integrative Medicine in the Management of Headache

by Deena Kuruvilla, MD In this month’s edition of Headache in the News, we are featuring an article from the British Medical Journal which highlights “Complementary and integrative medicine (CIM) in the management of headache.” In my headache practice, I am constantly asked about treatments that may complement conventional treatments such as prescription medications. In a 2009 Cephalalgia article, Gaul et al. report that nearly 82% of headache sufferers use CIM approaches and 50% of CIM users do not discuss their CIM treatments with their health care provider. While most headache specialists may be recommending proven treatments such as botulinum toxin and prescription medications, our...

Board & Committees

The AHS Board of Directors helps to guide the mission and objectives of the society. In addition to organizing events and educational symposia, they also perform research and provide support to headache professionals and patients.

Congratulations to the 2018 – 2020 Board of Directors!

President Editor of the Journal
Kathleen B. Digre, MD, FAHS Thomas N. Ward, MD, FAHS
Immediate Past President Executive Editor of the Journal
R. Allan Purdy, MD, FAHS Jason Roberts, PhD
President-Elect Section Chair
Peter J. Goadsby, MD, PhD, FAHS Mia Minen, MD, MPH, FAHS
Treasurer Associate Member Representative
Andrew C. Charles, MD, FAHS Carol A. Barch, MN, FNP-BC
Secretary Past President Advisors
Todd J. Schwedt, MD, MSCI, FAHS Robert B. Daroff, MD, FAHS
Chair, American Migraine Foundation Richard B. Lipton, MD, FAHS
David W. Dodick, MD, FAHS Elizabeth W. Loder, MD, MPH, FAHS
Corporate Liaison Lawrence C. Newman, MD, FAHS
Stewart J. Tepper, MD, FAHS Joel R. Saper, MD, FAHS
Members-at-Large Stephen D. Silberstein, MD, FAHS
Jessica Ailani, MD, FAHS Paul Winner, DO, FAHS
Dawn C. Buse, PhD, FAHS Pan Asian Liaison
Deborah I. Friedman, MD, MPH, FAHS Mamoru Shibata, MD, PhD
Christine Lay, MD, FAHS Pan American Liaison
Morris Levin, MD, FAHS Fabiola Dach Eckeli, MD, PhD
Matthew S. Robbins, MD, FAHS
Robert E. Shapiro, MD, PhD  
Stewart J. Tepper, MD, FAHS

*Board of Directors Disclosure List

What’s Hot at AHS 2017?

Meeting a new attendance record, 1000 headache and migraine specialists are descending upon Boston this year for the American Headache Society (AHS) 2017 Annual Meeting June 8 through June 11. With a high of 235 accepted abstracts on the latest research into treatment and disease epidemiology, which will be presented during scientific talks and 177 posters, the AHS scientific program committee chair said he's enthusiastic for this year's meeting — and for the field overall. In fact, he noted that the theme should be "hope" because of the proliferation of new therapeutic options. "It's not just hope in a vague...

AHS Meeting Release Veterans

Study Shows Veterans Who Suffered Traumatic Brain Injury While Deployed Have More Severe Headaches for Up to 11 Years Can cause disability and significantly affect employment, marriage and quality of life Boston, June 7, 2017 – A new study by the Veterans Administration shows that veterans who suffered a traumatic brain injury (TBI) while deployed in Afghanistan or Iraq are significantly more likely to have more severe headaches than veterans who did not have a TBI while deployed. This difference persisted for up to 11 years. The findings are being presented at this year’ 59th annual meeting of the American...

AHS Meeting Release Neuromodulation

  Promising Findings with Non-Invasive Medical Devices for Severe Headaches Presented at American Headache Society Meeting Approved and investigational devices may provide alternatives to medications Boston, June 7, 2017–Results from three studies with non-invasive medical devices offer hope to people suffering from migraine, a major disabling neurological disease that affects more than 36 million people in the United States, and episodic cluster headache, an extremely painful disease that occurs with attacks that last for weeks or months, followed by pain-free periods. The findings are being presented at this year’ 59th annual meeting of the American Headache Society, taking place June 8...

AHS Meeting Release C2GRP

Promising Results for First-Ever Preventive Migraine Treatment Class Presented at American Headache Society’s 59th Annual Scientific Meeting [MOUNT ROYAL, NJ, JUNE 7, 2017] – Clinical studies presented this week  at the 59th Annual Scientific Meeting The American Headache Society (AHS) support the efficacy and safety of antibodies targeting calcitonin gene-related peptide (CGRP) as a preventive therapy for both episodic and chronic migraine. The new class of treatment shows convincing data that blocking the CGRP pathway prevents migraine attacks. We’re in a genuine watershed moment with the very first class of migraine treatments that can prevent the attacks from actually happening,”...

AHS Meeting Release Pediatrics

Clinical Studies at American Headache Society 59th Annual Scientific Meeting Show Gap in Understanding of Migraine Diagnosis and Treatment in Pediatric Patients [MOUNT ROYAL, N.J., June 7, 2017] – At the American Headache Society (AHS)’s 59th Annual Scientific Meeting, leading migraine experts are presenting four clinical studies that deepen the understanding of migraine in children and adolescents, while also demonstrating that further research is needed on multiple fronts. Data highlighted show that children and young adults with migraine experience a range of  symptoms not usually considered typical in pediatric migraine, and that their desired outcomes contrast with how healthcare providers...

AHS Meeting Release Opioids

Study Shows Prochlorperazine is More Effective than the Opioid Hydromorphone for Acute Migraine, a Disabling Condition that Causes 1.2 million Visits to US Emergency Departments per Year First Randomized Double-Blind Comparative Study of These Drugs for Emergency Department Migraine Visits Boston, June 7, 2017 – A new comparative study shows that, in patients who visit the emergency department for acute migraine treatment, prochorperazine is more effective than the opioid drug, hydromorphone. The difference was so substantial that the trial was halted early.  The findings are being presented at this year’ 59th annual meeting of the American Headache Society, taking place...

AHS Meeting Release Latebreakers

Late-Breaking Findings on Migraine and New Investigational Treatments Presented at 2017 American Headache Society Annual Scientific Meeting Boston, June 7, 2017 – The American Headache Society (AHS) announced results from four late-breaking studies that will be presented at the 59th Annual Scientific Meeting, June 8 – 11, 2017 in Boston, Massachusetts. They include findings on new, investigational treatments for acute migraine, possible similarities between colicky infants and migraine sufferers, and headaches following traumatic brain injury. The AHS Annual Scientific Meeting brings together more than 1,000 migraine and headache specialists from around the world. “These studies show the very considerable potential...